RBC Capital analyst Brian Abrahams downgraded Sage Therapeutics (NASDAQ: SAGE) from Outperform to Sector Perform with a price target of $25.00 (from $71.00).

For an analyst ratings summary and ratings history on Sage Therapeutics click here. For more ratings news on Sage Therapeutics click here.

Shares of Sage Therapeutics closed at $36.10 yesterday.